Blog

Merck is planning to sell a subcutaneous version of its blockbuster Keytruda that can be injected rather than administered intravenously.  Yet, standing in the way of that is a growing portfolio of patents recently acquired by Halozyme Therapeutics.  In 2024, Halozyme was awarded numerous patents covering modified PH20 hyaluronidase polypeptides.  Merck immediately went to the Patent Office and filed petitions for the patents to be cancelled.  What is the likelihood Merck’s patent challenges will succeed?  Or Merck will be compelled to sign a license for Halozyme’s patents.